公开(公告)号：US20240228608A9

公开(公告)日：2024-07-11

申请号：US18348244

申请日：2023-07-06

Applicant: Xencor, Inc.

Inventor： Matthew S. Faber ,  Sung-Hyung Lee ,  Yoon Kyung Kim ,  Jing Qi ,  Kendra N. Avery ,  Seung Y. Chu ,  Alex Nisthal ,  Matthew J. Bernett ,  John R. Desjarlais ,  Chad Borchert

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/46 ,  C12N15/63

CPC classification number: C07K16/28 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/468 ,  C12N15/63

Abstract: Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.

公开(公告)号：US20240132584A1

公开(公告)日：2024-04-25

申请号：US18348244

申请日：2023-07-05

Applicant: Xencor, Inc.

Inventor： Matthew S. Faber ,  Sung-Hyung Lee ,  Yoon Kyung Kim ,  Jing Qi ,  Kendra N. Avery ,  Seung Y. Chu ,  Alex Nisthal ,  Matthew J. Bernett ,  John R. Desjarlais ,  Chad Borchert

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/46 ,  C12N15/63

CPC classification number: C07K16/28 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/468 ,  C12N15/63

Abstract: Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.

公开(公告)号：US20230272114A1

公开(公告)日：2023-08-31

申请号：US18087157

申请日：2022-12-22

Applicant: Xencor, Inc.

Inventor： John R. Desjarlais ,  Seung Y. Chu ,  Holly M. Horton ,  Matthew J. Bernett

IPC: C07K16/42 ,  A61P37/08 ,  C07K16/46

CPC classification number: C07K16/4291 ,  A61P37/08 ,  C07K16/464 ,  C07K2317/24 ,  C07K2317/92 ,  C07K2317/52 ,  C07K2317/76 ,  A61K2039/505

Abstract: The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.

公开(公告)号：US20220289839A1

公开(公告)日：2022-09-15

申请号：US17690702

申请日：2022-03-09

Applicant: Xencor, Inc.

Inventor： Matthew S. Faber ,  Sung-Hyung Lee ,  Yoon Kyung Kim ,  Jing Qi ,  Kendra N. Avery ,  Seung Y. Chu ,  Alex Nisthal ,  Matthew J. Bernett ,  John R. Desjarlais ,  Chad Borchert

IPC: C07K16/28 ,  C07K16/46 ,  A61P35/00 ,  C12N15/63

Abstract: Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.

公开(公告)号：US10858451B2

公开(公告)日：2020-12-08

申请号：US15786252

申请日：2017-10-17

Applicant: XENCOR, INC.

Inventor： Matthew J. Bernett ,  Seung Y. Chu ,  Gregory Moore ,  John Desjarlais

IPC: C07K16/40 ,  C07K16/28 ,  C07K16/30 ,  C07K16/18 ,  A61K39/00 ,  C07K16/46

Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.

公开(公告)号：US20200332024A1

公开(公告)日：2020-10-22

申请号：US16783032

申请日：2020-02-05

Applicant: Xencor, Inc.

Inventor： John R. Desjarlais ,  Seung Y. Chu ,  Holly M. Horton ,  Matthew J. Bernett

IPC: C07K16/42 ,  A61P37/08 ,  C07K16/46

Abstract: The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.

公开(公告)号：US20170335013A1

公开(公告)日：2017-11-23

申请号：US15461374

申请日：2017-03-16

Applicant: Xencor, Inc.

Inventor： John R. Desjarlais ,  Seung Y. Chu ,  Holly M. Horton ,  Matthew J. Bernett

IPC: C07K16/42 ,  C07K16/46

Abstract: The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.